Lupus Research Alliance Applauds U.S. FDA Approval of Gazyva® (Obinutuzumab) for Lupus Nephritis
The Lupus Research Alliance applauds the approval by the U.S. Food and Drug Administration of Gazyva® (obinutuzumab) from Genentech for the treatment of adults with active lupus nephritis in combination with standard of care. This is a major step forward for the entire lupus community, as it is the only anti-CD20 monoclonal antibody targeting an … Lupus Research Alliance Applauds U.S. FDA Approval of Gazyva® (Obinutuzumab) for Lupus Nephritis
